secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001493152-23-016947
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx Q1 2023 net loss $3.3M; Phase III data shows 60% survival benefit
--------------------------------------------------------------------------

- Cash and equivalents were $3.7M at March 31, 2023; net loss $3.3M vs $3.0M in Q1 2022.
- Phase III TIGeR-PaC interim analysis: 60% survival benefit, >65% reduction in side effects vs systemic chemo.
- Closed $5M registered direct offering subsequent to quarter end.
- Appointed Robert J. Spiegel (former CMO of Schering-Plough) to Board; Leesa Gentry as SVP Clinical Operations.
- Issued 8th U.S. patent extending RenovoTAMP therapy platform IP coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223016947/0001493152-23-016947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223016947/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer